Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2009-10-20 AGM Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
CEO Presentation to AGM 2009 37 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting October 2009' and contains detailed company overview, milestones, clinical trial phases, product development, market access, and regulatory updates. It includes presentations and materials typically shared during an AGM, such as management updates, product pipeline, clinical trial results, and strategic outlook. There is no indication that this is a full annual report (10-K), earnings release, or other regulatory filing. The content is consistent with AGM Information, which is presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), supporting that it is a full AGM presentation rather than a brief announcement or report publication notice.
2009-10-20 English
Pharmaxis Quarterly Report to Shareholders - Sept 2009 8 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report to Shareholders' and covers activities and updates for the quarter July to September 2009. It includes detailed operational updates, clinical trial progress, marketing and regulatory activities, corporate news including a Nasdaq delisting, and upcoming events. The content includes substantive financial and operational data, management commentary, and forward-looking statements typical of an interim or quarterly report. It is not a brief announcement or a presentation, nor is it a full annual report or an earnings release with just highlights. The length (15,000 characters) and depth of content confirm it is a comprehensive quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2009
2009-10-13 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements, payments to directors, financing facilities, reconciliation of cash, and compliance statements. The report covers a specific quarter ending 30 September 2009, indicating it is a periodic financial report shorter than a full fiscal year. The presence of actual financial statements and substantive financial data confirms it is a financial report rather than an announcement or certification. The document matches the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial information for a quarter. Q1 2009
2009-10-13 English
Investor Presentation - Quarterly Conference Call 21 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from October 2009 by Pharmaxis, focusing on clinical trial phases, product pipelines, market access milestones, regulatory submissions, and financial statement summaries. It includes forward-looking statements, clinical trial data, regulatory status updates, and financial highlights for a quarter ending 30-Sep-09. The content is typical of an investor presentation, providing strategic, clinical, and financial information to investors rather than a formal regulatory filing or full financial report. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The presence of detailed clinical and market information alongside financial data aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and the nature of the content confirm it is the presentation itself, not just an announcement or a certification. Therefore, the appropriate classification is Investor Presentation (IP).
2009-10-13 English
Quarterly Investor Conference Call 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing an upcoming investor conference call to discuss the September 2009 Quarterly Report. It provides details about the teleconference timing, access numbers, and mentions that a recording will be available later. The document does not contain the actual quarterly financial data or analysis, only an announcement of the call and report release. According to the rules, announcements of conference calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this is only an announcement of the call, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2009-10-12 English
Second CF Trial Passes Recruitment Target 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Pharmaxis has passed the recruitment target for its second pivotal Phase 3 clinical trial of Bronchitol for cystic fibrosis. It provides details about the trial design, expected data availability, regulatory status, and future marketing application plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about clinical trial progress and regulatory milestones, not a financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial or governance report. It is also not a report publication announcement or certification. The content fits best as a general regulatory announcement or corporate update, which falls under Regulatory Filings (RNS). The document length is about 4874 characters, which is consistent with a media release rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2009-09-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.